Medicenna Therapeutics Future Growth
Future criteria checks 2/6
Medicenna Therapeutics is forecast to grow earnings and revenue by 42% and 59.4% per annum respectively while EPS is expected to grow by 40.4% per annum.
Key information
42.0%
Earnings growth rate
40.4%
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | 59.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Feb 2024 |
Recent future growth updates
Recent updates
Medicenna extends period to exercise certain warrants
Sep 30Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment
Sep 13Medicenna Therapeutics GAAP EPS of -$0.07 in-line
Aug 15Medicenna Therapeutics stock slides on launch of units offering
Aug 08Medicenna Therapeutics reports FY results
May 28Medicenna posts positive data from mid-stage brain cancer study
May 07Medicenna announces ATM sales facility for $25M
Dec 31Medicenna Therapeutics reports Q2 results
Nov 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 15 | -9 | N/A | -15 | 1 |
3/31/2026 | 2 | -19 | N/A | 56 | 3 |
3/31/2025 | 1 | -19 | N/A | 16 | 3 |
3/31/2024 | N/A | -16 | N/A | -16 | 4 |
12/31/2023 | N/A | -15 | -14 | -14 | N/A |
9/30/2023 | N/A | -12 | -13 | -13 | N/A |
6/30/2023 | N/A | -9 | -14 | -14 | N/A |
3/31/2023 | N/A | -10 | -13 | -13 | N/A |
12/31/2022 | N/A | -9 | -13 | -13 | N/A |
9/30/2022 | N/A | -13 | -16 | -16 | N/A |
6/30/2022 | N/A | -20 | -21 | -21 | N/A |
3/31/2022 | N/A | -23 | -24 | -24 | N/A |
12/31/2021 | N/A | -25 | -23 | -23 | N/A |
9/30/2021 | N/A | -26 | -20 | -20 | N/A |
6/30/2021 | N/A | -21 | -17 | -17 | N/A |
3/31/2021 | N/A | -17 | -15 | -15 | N/A |
12/31/2020 | N/A | -14 | -16 | -16 | N/A |
9/30/2020 | N/A | -11 | -14 | -14 | N/A |
6/30/2020 | N/A | -9 | -5 | -5 | N/A |
3/31/2020 | N/A | -8 | -5 | -5 | N/A |
12/31/2019 | N/A | -7 | -5 | -5 | N/A |
9/30/2019 | N/A | -6 | -5 | -5 | N/A |
6/30/2019 | N/A | -5 | -8 | -8 | N/A |
3/31/2019 | N/A | -5 | -8 | -8 | N/A |
12/31/2018 | N/A | -5 | -9 | -9 | N/A |
9/30/2018 | N/A | -5 | -10 | -10 | N/A |
6/30/2018 | N/A | -6 | -11 | -11 | N/A |
3/31/2018 | N/A | -7 | -10 | -10 | N/A |
12/31/2017 | N/A | -11 | -10 | -10 | N/A |
9/30/2017 | N/A | -11 | N/A | -8 | N/A |
6/30/2017 | N/A | -10 | N/A | -8 | N/A |
3/31/2017 | N/A | -8 | N/A | -7 | N/A |
12/31/2016 | N/A | -3 | N/A | -6 | N/A |
9/30/2016 | N/A | -2 | N/A | -5 | N/A |
6/30/2016 | N/A | -1 | N/A | -4 | N/A |
3/31/2016 | N/A | -1 | N/A | -3 | N/A |
3/31/2015 | N/A | -1 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDNA.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDNA.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDNA.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDNA.F's revenue (59.4% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: MDNA.F's revenue (59.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDNA.F's Return on Equity is forecast to be high in 3 years time